StockNews.com initiated coverage on shares of 22nd Century Group (NASDAQ:XXII – Free Report) in a research report released on Friday. The brokerage issued a sell rating on the biotechnology company’s stock.
22nd Century Group Stock Performance
NASDAQ XXII opened at $0.29 on Friday. The firm’s fifty day moving average price is $0.53 and its two-hundred day moving average price is $4.82. The stock has a market cap of $2.39 million, a PE ratio of 0.00 and a beta of 1.41. 22nd Century Group has a fifty-two week low of $0.24 and a fifty-two week high of $17.06.
22nd Century Group (NASDAQ:XXII – Get Free Report) last posted its earnings results on Tuesday, August 13th. The biotechnology company reported ($0.36) earnings per share for the quarter. 22nd Century Group had a negative return on equity of 380.39% and a negative net margin of 275.12%. The business had revenue of $7.95 million for the quarter.
Institutional Investors Weigh In On 22nd Century Group
22nd Century Group Company Profile
22nd Century Group, Inc, a tobacco products company, engages in the sale and distribution of its own proprietary new reduced nicotine tobacco products. The company offers reduced nicotine content tobacco plants and very low nicotine combustible cigarette products. It also provides contract manufacturing services for conventional combustible tobacco products for third-party brands.
Read More
- Five stocks we like better than 22nd Century Group
- Canadian Penny Stocks: Can They Make You Rich?
- The Average 401k Balance by Age Explained
- How to Use Stock Screeners to Find Stocks
- 3 Uranium Stocks To Gain as Microsoft Goes Nuclear to Power AI
- How to buy stock: A step-by-step guide for beginners
- Biotech Boom Ahead? Key Stocks and ETFs to Watch Now
Receive News & Ratings for 22nd Century Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 22nd Century Group and related companies with MarketBeat.com's FREE daily email newsletter.